BIO Submits Comments to Steve Pearson re: ICER Value Framework
<div>
Steven D. Pearson, MD, MSc, FRCP</div>
<div>
President, Institute for Clinical and Economic Review</div>
<div>
One State Street</div>
<div>
Suite 1050</div>
<div>
Boston, MA 02109 USA</div>
<div>
</div>
<div>
BY ELECTRONIC DELIVERY</div>
<div>
</div>
<div>
RE: Institute for Clinical and Economic Review (ICER) Value Framework</div>
<div>
</div>
<div>
Dear Dr. Pearson:</div>
<div>
</div>
<div>
On behalf of the Biotechnology Industry Organization (BIO), I would like to submit the following feedback with respect to ICER’s Value Framework, presented on September 15, 2015. BIO advocates on behalf of biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO’s members develop medical products and technologies to treat patients afflicted with serious diseases, to delay the onset of these diseases, or to prevent them in the first place. In that way, our members’ novel therapeutics, vaccines, and diagnostics not only have improved health outcomes, but also have reduced healthcare expenditures due to fewer physician office visits, hospitalizations, and surgical interventions.</div>
